CA 27-29 Test

If you have been treated for breast cancer or are living with advanced disease, your biggest question between scans is simple: is the treatment working, and is the cancer staying away? CA 27-29 is one of only two FDA-approved blood tests designed to help answer that question in real time, without imaging. A rising level can flag disease progression or recurrence two to nine months before it shows up on a scan or physical exam.

This is not a screening test. It will not catch breast cancer in someone who has never been diagnosed. Its sensitivity in early-stage disease is low, somewhere between 10% and 35%. But for people with a history of breast cancer, especially metastatic disease, serial CA 27-29 measurements offer a running scorecard of what the cancer is doing inside your body.

What CA 27-29 Actually Measures

CA 27-29 (Cancer Antigen 27-29) measures a fragment of a large protein called MUC1 (Mucin 1) that normally sits on the outer surface of cells lining your breast ducts, lungs, pancreas, and digestive tract. In healthy tissue, MUC1 acts as a protective coating, keeping those surfaces lubricated and shielding them from damage. The protein stays anchored to the cell surface and very little of it ends up in your blood.

In breast cancer, two things change. First, cancer cells produce far more MUC1 than normal cells do, and they coat themselves with it in a disorganized way. Second, pieces of the protein break off and spill into the bloodstream. That spillover is what the CA 27-29 test detects. The more cancer cells are present and the more aggressively they are growing, the more MUC1 fragments end up circulating in your blood.

CA 27-29 vs. CA 15-3: Two Tests for the Same Protein

You may see CA 15-3 listed alongside or instead of CA 27-29. Both tests detect pieces of MUC1, but they use different antibodies that latch onto different spots on the protein. In a large analysis of over 37,000 paired results, the two tests showed a correlation of 0.967 (essentially moving in lockstep) and agreed on whether a result was normal or abnormal 93.7% of the time. Despite this tight agreement, the two tests are not interchangeable on a number-to-number basis because they use different measurement scales.

If your oncologist has been tracking you with one of these tests, stick with it. Switching mid-stream introduces noise that can mask a real trend or create a false alarm.

Breast Cancer Monitoring

CA 27-29's primary clinical role is monitoring breast cancer after diagnosis. In metastatic breast cancer, the test picks up disease activity in roughly 70% to 79% of cases. That sensitivity is highest when cancer has spread to the liver or bones. In one study, liver metastases were significantly associated with abnormal CA 27-29 readings. Serial measurements matched the actual clinical course of the disease about 81% of the time, meaning the number tracked closely with whether the cancer was responding, stable, or progressing.

The most powerful use of CA 27-29 is detecting recurrence early. Rising levels can precede clinical detection of returning cancer by two to nine months. That lead time can allow your treatment team to act before the cancer becomes visible on imaging. However, guidelines from the NCCN caution that a single rising value should rarely be used alone to change treatment, because a temporary spike (sometimes called a tumor flare) can occur even when treatment is working.

Beyond Breast Cancer

CA 27-29 is not breast-cancer exclusive. Because MUC1 is produced by cells in many organs, elevations can occur in ovarian cancer (up to 60% of cases), as well as in endometrial, colorectal, and pancreatic cancers, though with lower sensitivity. In a study of metastatic adenocarcinoma patients receiving immunotherapy, pre-treatment CA 27-29 above 40 U/mL predicted poorer survival across breast, ovarian, colorectal, and pancreatic cancers. The most informative cutoffs varied by cancer type: 22 U/mL for colorectal and 60 U/mL for pancreatic.

That said, the test's specificity drops as you broaden its application beyond breast cancer. CA 27-29 was not designed for and has not been validated as a screening tool for these other malignancies.

Prognostic Value in Early Breast Cancer

Even in early-stage disease, the pre-treatment CA 27-29 level carries prognostic weight. In the SUCCESS-A trial, which followed 2,687 women with high-risk early breast cancer, a pre-chemotherapy CA 27-29 level was independently associated with disease-free survival after adjusting for tumor size, lymph node involvement, hormone receptor status, HER2, and tumor grade. This association held in women whose cancer had spread to lymph nodes. In other words, starting with a higher number predicted a worse outcome, even after accounting for the usual risk factors.

Reference Ranges

Baseline CA 27-29 levels vary by age and hormonal status. Postmenopausal women tend to have higher levels than premenopausal women, even in the absence of any disease. Body mass index, race, and smoking history can also shift baseline readings. Keep these factors in mind when interpreting your result.

These tiers are drawn from published research and manufacturer thresholds. Your lab may use different assays and cutpoints. Compare your results within the same lab over time for the most meaningful trend.

When Results Can Be Misleading

A single CA 27-29 reading can mislead you in several ways. The most common source of confusion is benign elevation. Liver disease (hepatitis, cirrhosis), pulmonary fibrosis, benign breast disease, ovarian cysts, and endometriosis can all push the number above 38 U/mL without any cancer being present. If you have any of these conditions, your baseline may simply run higher than the standard cutoff.

Tumor flare is another trap. When treatment is actually working and cancer cells are dying, they can release a burst of MUC1 fragments into the blood, temporarily spiking your CA 27-29. This can look like progression when it is actually the opposite. The NCCN recommends against making treatment changes based on a single rising value for exactly this reason.

Menopausal status also matters. Postmenopausal women have higher baseline levels, so a reading of 40 U/mL in a postmenopausal woman may carry less clinical significance than the same number in a 35-year-old. Always interpret the number in the context of your personal baseline and clinical picture.

Tracking Your Trend

A single CA 27-29 value is a snapshot. Its real power comes from tracking it over time. Because the test has limited sensitivity in early-stage cancer (10% to 35%) and can be elevated by benign conditions, any single result carries uncertainty. But a consistent trend, three or more readings moving in the same direction, tells a much clearer story.

If you are being monitored after breast cancer treatment, get a baseline reading once treatment is complete and you are in remission. Retest every three to six months for the first two to three years (the period when recurrence risk is highest), then at least every six to twelve months thereafter. If you notice a rising trend across two or more draws, discuss it with your oncologist before the next scheduled scan. The two-to-nine-month lead time that CA 27-29 provides over imaging is only useful if you are testing frequently enough to catch the rise.

Always use the same lab for serial measurements. Switching labs or assays introduces variation that can create false trends. The goal is to see your own trajectory clearly, and that requires consistency.

What This Test Cannot Do

CA 27-29 is not a screening test. It lacks the sensitivity to detect breast cancer in people who have never been diagnosed. Only 10% to 35% of people with early-stage breast cancer will have an elevated reading. The FDA has approved CA 27-29 specifically for monitoring disease activity in people who already have a breast cancer diagnosis, not for primary detection.

It is also not a standalone decision tool. An elevated level does not confirm cancer is present or progressing, and a normal level does not guarantee it is gone. CA 27-29 is most useful as one data point alongside imaging, physical exams, and clinical symptoms. When all of these signals align, the clinical picture becomes much sharper.